{"id":"fludeoxyglucose-f-18-fdg","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Allergic reaction (rare)"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FDG is a radiopharmaceutical tracer that mimics glucose metabolism. Cancer cells and inflamed tissues typically exhibit elevated glucose uptake due to increased metabolic demand. The fluorine-18 isotope emits positrons that annihilate with electrons to produce gamma rays, which are detected by PET scanners to create metabolic images of the body.","oneSentence":"Fludeoxyglucose F-18 is a glucose analog labeled with fluorine-18 that accumulates in tissues with high metabolic activity, enabling detection via positron emission tomography (PET) imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:37.649Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Detection and staging of cancer (lung, breast, colorectal, lymphoma, melanoma)"},{"name":"Evaluation of dementia and neurodegenerative disorders"},{"name":"Assessment of myocardial viability in cardiac disease"}]},"trialDetails":[{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04569591","phase":"NA","title":"DDAVP for Pituitary Adenoma","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2026-03-09","conditions":"Cushing's Disease, Pituitary Adenoma","enrollment":22},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT02193425","phase":"EARLY_PHASE1","title":"Reliability of the Human Brain Connectome","status":"COMPLETED","sponsor":"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","startDate":"2015-06-08","conditions":"Normal Physiology","enrollment":112},{"nctId":"NCT04533750","phase":"PHASE1","title":"Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-20","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT01934660","phase":"","title":"Links Between Inflammation and Cardiometabolic Diseases","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2013-12-02","conditions":"Diabetes Mellitus, Cardiovascular Disease, Healthy Volunteer","enrollment":150},{"nctId":"NCT06465017","phase":"NA","title":"ImmunoPET Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) in Thyroid Cancer","status":"TERMINATED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-01-04","conditions":"Tumor, Solid Tumor, Thyroid Cancer","enrollment":149},{"nctId":"NCT06503146","phase":"PHASE2","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-09-09","conditions":"Sarcoma, Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC), Mesothelioma","enrollment":320},{"nctId":"NCT04214262","phase":"PHASE3","title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-13","conditions":"Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":480},{"nctId":"NCT05286801","phase":"PHASE1, PHASE2","title":"Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-17","conditions":"Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma","enrollment":86},{"nctId":"NCT07494162","phase":"NA","title":"Imaging Metabolic and Perfusion Changes in Acupuncture Therapy for Myofascial Pain Syndrome","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-04","conditions":"Myofascial Pain Syndrome (MPS), Chronic Low-back Pain (cLBP)","enrollment":64},{"nctId":"NCT04943211","phase":"PHASE3","title":"Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging","status":"RECRUITING","sponsor":"Anna Raciborska","startDate":"2021-04-01","conditions":"Histiocytosis","enrollment":150},{"nctId":"NCT05756270","phase":"","title":"Clinical Applicability of pCASL as a Substitute for FDG-PET in MCI and SCD Patients","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2022-06-03","conditions":"Mild Cognitive Impairment, Subjective Cognitive Decline","enrollment":150},{"nctId":"NCT03683355","phase":"","title":"Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves.","status":"COMPLETED","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-11-09","conditions":"Infective Endocarditis","enrollment":30},{"nctId":"NCT00006421","phase":"","title":"Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-10-25","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT04316117","phase":"PHASE2","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-09-15","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma","enrollment":138},{"nctId":"NCT07487883","phase":"","title":"Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-03-15","conditions":"Non-Small Cell Lung Cancer, Malignant Neoplasm, Pulmonary Nodules","enrollment":80},{"nctId":"NCT04166318","phase":"PHASE2","title":"Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2020-01-02","conditions":"Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma","enrollment":252},{"nctId":"NCT04804371","phase":"NA","title":"Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2021-03-04","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT07479095","phase":"NA","title":"Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung Adenocarcinoma","status":"RECRUITING","sponsor":"Fondazione del Piemonte per l'Oncologia","startDate":"2025-07-03","conditions":"Lepidic-Predominant Lung Adenocarcinoma, Lung Adenocarcinoma","enrollment":30},{"nctId":"NCT05191940","phase":"NA","title":"Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)","status":"RECRUITING","sponsor":"EBG MedAustron GmbH","startDate":"2022-05-16","conditions":"Pancreas Cancer","enrollment":30},{"nctId":"NCT07482072","phase":"","title":"Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2026-03","conditions":"Alzheimer Dementia (AD), Diabete Type 2","enrollment":60},{"nctId":"NCT05931302","phase":"NA","title":"Initial Staging of Lobular Breast Carcinoma: Head to Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","startDate":"2023-11-16","conditions":"Lobular Breast Carcinoma","enrollment":40},{"nctId":"NCT04143516","phase":"PHASE2, PHASE3","title":"Tissue Analysis After Tumor Ablation for Liver Metastases Leading to Immediate Retreatment","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-10-25","conditions":"Liver Metastases","enrollment":200},{"nctId":"NCT04119024","phase":"PHASE1","title":"Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Anusha Kalbasi","startDate":"2025-10-07","conditions":"Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":18},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT06144853","phase":"","title":"The PIPAC-OPC7 Study: The Use of PET/CT Scans as a Method of Evaluation in Patients Treated With PIPAC, a Pilot Study.","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2024-03-15","conditions":"Peritoneal Cancer, Peritoneal Metastases, Peritoneal Carcinomatosis","enrollment":34},{"nctId":"NCT07471776","phase":"PHASE2","title":"Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-03-11","conditions":"Metastatic Breast Cancer ( HER2 Negative)","enrollment":45},{"nctId":"NCT00194298","phase":"","title":"FDG-PET Imaging in Complicated Diabetic Foot","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2002-10","conditions":"Diabetic Foot Disease","enrollment":240},{"nctId":"NCT00194285","phase":"","title":"FDG-PET Imaging in Painful Joint Prosthesis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2001-03","conditions":"Painful Joint Prostheses","enrollment":530},{"nctId":"NCT04812080","phase":"NA","title":"EXPLORER PET/CT: Evaluation of Healthy Individuals From Racial/Ethnic Minority Populations","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-08-18","conditions":"Healthy Volunteers From Racial/Ethnic Minority Populations","enrollment":20},{"nctId":"NCT07463300","phase":"","title":"A Hierarchical Multi-modal AI Framework for Pathological and Genetic Subtyping of Lung Cancer Based on PET/CT Imaging","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-08-01","conditions":"Lung Cancer","enrollment":5500},{"nctId":"NCT05876858","phase":"EARLY_PHASE1","title":"EXPLORER Total Body PET/CT Imaging for Myofascial Pain","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2023-06-13","conditions":"Myofascial Pain","enrollment":53},{"nctId":"NCT05160480","phase":"","title":"A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, Davis","startDate":"2024-06-07","conditions":"Prostate Cancer, Breast Cancer, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT04478318","phase":"NA","title":"Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2020-06-01","conditions":"Lung Neoplasm, Lymphoma, Melanoma","enrollment":180},{"nctId":"NCT04020978","phase":"NA","title":"Parametric PET of Genitourinary Cancer","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2019-07-16","conditions":"Genitourinary Cancer","enrollment":11},{"nctId":"NCT04841707","phase":"NA","title":"Total-Body Parametric 18F-FDG PET of COVID-19","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2021-05-10","conditions":"Covid19","enrollment":13},{"nctId":"NCT06014515","phase":"EARLY_PHASE1","title":"Single-tracer Multiparametric PET Imaging","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2024-02-14","conditions":"Healthy Subjects, Cardiovascular Disease","enrollment":60},{"nctId":"NCT02379377","phase":"PHASE1","title":"18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-15","conditions":"Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma","enrollment":110},{"nctId":"NCT07458906","phase":"NA","title":"DLL3-Targeted PET/CT in Neuroendocrine Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2025-12-01","conditions":"DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer","enrollment":60},{"nctId":"NCT04454450","phase":"NA","title":"Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-06-22","conditions":"Ovarian Cancer, High Grade Ovarian Serous","enrollment":10},{"nctId":"NCT07454096","phase":"PHASE4","title":"Application of Radiomics for Diagnosis and Follow-up of Cardiovascular Device Infections: PREDICT Study","status":"NOT_YET_RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2026-04-30","conditions":"Cardiac Disease, Device Related Infection","enrollment":200},{"nctId":"NCT03853915","phase":"NA","title":"FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2019-04-23","conditions":"Cervical Cancer","enrollment":64},{"nctId":"NCT07442292","phase":"","title":"PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-02","conditions":"Lung Cancer (NSCLC), Lung Cancer (SCLC), Melanoma (Skin Cancer)","enrollment":40},{"nctId":"NCT07004673","phase":"","title":"18F FDG and 68Ga FAPI PET/MR Imaging of Carotid Artery Plaque Vulnerability: A Clinical Study in Carotid Artery Plaque Patients","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-04-12","conditions":"Carotid Artery Plaque, Ischemic Stroke, PET / MR","enrollment":100},{"nctId":"NCT07448727","phase":"","title":"Impact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT","status":"RECRUITING","sponsor":"University of Rome Tor Vergata","startDate":"2024-11-20","conditions":"Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT05321316","phase":"NA","title":"Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2026-05-31","conditions":"Urothelial Carcinoma","enrollment":20},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":"Mantle Cell Lymphoma","enrollment":421},{"nctId":"NCT07449858","phase":"","title":"18F-FDG PET/CT Radiomics Models for Precision Diagnosis and Prognosis in NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-07-01","conditions":"Non Small Cell Lung Cancer","enrollment":500},{"nctId":"NCT05436093","phase":"NA","title":"CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors","status":"RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2022-06-23","conditions":"Solid Tumor","enrollment":15},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT06502691","phase":"PHASE1, PHASE2","title":"[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-02-26","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma","enrollment":22},{"nctId":"NCT05710328","phase":"PHASE2","title":"Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2023-05-10","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma","enrollment":235},{"nctId":"NCT07443696","phase":"PHASE2","title":"PET Myocardial Fatty-acid Metabolic Imaging With XTR003 Injection and 18F-FDG to Assess Myocardial Viability in Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2025-12-18","conditions":"Ischemic Cardiomyopathy, Heart Failure","enrollment":40},{"nctId":"NCT04667585","phase":"NA","title":"Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx","status":"RECRUITING","sponsor":"Duke University","startDate":"2021-04-12","conditions":"Oropharynx Cancer","enrollment":120},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT06814587","phase":"","title":"Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-07-01","conditions":"Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)","enrollment":15},{"nctId":"NCT06103838","phase":"PHASE2","title":"18F-Fluciclovine PET/CT in Multiple Myeloma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-03-25","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM)","enrollment":60},{"nctId":"NCT02125786","phase":"PHASE2","title":"A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-07","conditions":"Ependymoma","enrollment":68},{"nctId":"NCT04293562","phase":"PHASE3","title":"A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-21","conditions":"Acute Myeloid Leukemia","enrollment":1186},{"nctId":"NCT07430475","phase":"","title":"Utility of 18F-FDG PET/CT for Suspected Infection in the Inpatient Setting: a Single Centre Retrospective Cohort Study","status":"COMPLETED","sponsor":"University of Adelaide","startDate":"2022-01-04","conditions":"Fever of Unknown Origin, Inflammation of Unknown Origin, Fever","enrollment":266},{"nctId":"NCT07431255","phase":"","title":"Generation of Synthetic [18F]FDG PET From Early-Phase Amyloid PET in Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2026-03-01","conditions":"Alzheimer Disease (AD)","enrollment":35},{"nctId":"NCT07419867","phase":"PHASE2","title":"A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Breast Cancer Using PET/MRI","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-01","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT03507257","phase":"","title":"Longitudinal Early-onset Alzheimer's Disease Study Protocol","status":"RECRUITING","sponsor":"Indiana University","startDate":"2018-04-30","conditions":"Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment","enrollment":850},{"nctId":"NCT05647564","phase":"NA","title":"PET/CT Characterization of Treatment Resistance","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2023-03-06","conditions":"Prostate Cancer","enrollment":25},{"nctId":"NCT06820957","phase":"PHASE2, PHASE3","title":"Testing a New Combination of Anti-cancer Drugs in Patients Newly Diagnosed With Ewing Sarcoma Who Have Cancer That Has Spread to Other Parts of the Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-11-10","conditions":"CIC-Rearranged Sarcoma, Metastatic Ewing Sarcoma, Metastatic High Grade Sarcoma","enrollment":437},{"nctId":"NCT02226276","phase":"NA","title":"Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2015-01-07","conditions":"Bone Metastases, HER2-positive Breast Cancer, Liver Metastases","enrollment":10},{"nctId":"NCT07285993","phase":"PHASE2","title":"Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET","status":"NOT_YET_RECRUITING","sponsor":"Randy Yeh","startDate":"2026-02-16","conditions":"Breast Cancer, Metastatic Invasive Lobular Breast Cancer","enrollment":15},{"nctId":"NCT06335914","phase":"NA","title":"Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-04-03","conditions":"Advanced Prostate Cancer","enrollment":30},{"nctId":"NCT04016818","phase":"EARLY_PHASE1","title":"Pilot Breast-Dedicated PET Camera With 1 Millimeter Spatial Resolution","status":"NOT_YET_RECRUITING","sponsor":"Stanford University","startDate":"2026-06","conditions":"Breast Cancer","enrollment":20},{"nctId":"NCT05775939","phase":"NA","title":"PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-01-20","conditions":"Lung Carcinoma, Esophageal Carcinoma","enrollment":20},{"nctId":"NCT05121012","phase":"","title":"Synaptic Loss in Multiple System Atrophy","status":"RECRUITING","sponsor":"University of Exeter","startDate":"2021-09-01","conditions":"Multiple System Atrophy, Progressive Supranuclear Palsy (PSP)","enrollment":36},{"nctId":"NCT04273555","phase":"PHASE1, PHASE2","title":"Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-01","conditions":"HER2-positive Breast Cancer","enrollment":""},{"nctId":"NCT04359732","phase":"NA","title":"Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2020-05-08","conditions":"Esophageal Cancer, Esophageal Neoplasms","enrollment":121},{"nctId":"NCT01237054","phase":"PHASE2","title":"Imaging in MGUS, SMM and MM","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-17","conditions":"Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance","enrollment":31},{"nctId":"NCT06175390","phase":"PHASE2","title":"Tiragolumab, Atezolizumab and Chemotherapy in Triple Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Curie","startDate":"2024-03-27","conditions":"Triple Negative Breast Cancer","enrollment":81},{"nctId":"NCT04459273","phase":"PHASE1","title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-08-27","conditions":"Bladder Carcinoma, Cervical Carcinoma, Cholangiocarcinoma","enrollment":26},{"nctId":"NCT07178587","phase":"NA","title":"Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2026-02-02","conditions":"Hepatocellular Carcinoma (HCC), Gastro-Entero-Pancreatic Tumors (GEPs)","enrollment":28},{"nctId":"NCT06083103","phase":"","title":"Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)","status":"RECRUITING","sponsor":"Centre Paul Strauss","startDate":"2023-10-12","conditions":"Cervical Cancer","enrollment":50},{"nctId":"NCT07366710","phase":"NA","title":"Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2024-11-05","conditions":"Glucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)","enrollment":36},{"nctId":"NCT06500065","phase":"NA","title":"68Ga-DOTATATE PET/CT for the Diagnosis of Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-09-30","conditions":"Soft Tissue Sarcoma","enrollment":30},{"nctId":"NCT06836726","phase":"PHASE2","title":"Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2026-05-27","conditions":"Castration Resistant Prostate Cancer","enrollment":35},{"nctId":"NCT06145633","phase":"PHASE2","title":"Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-09-18","conditions":"Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":15},{"nctId":"NCT04692103","phase":"PHASE2","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-10","conditions":"Estrogen Receptor Positive, Primary or Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7","enrollment":2},{"nctId":"NCT06225505","phase":"NA","title":"Early Detection of Triple Negative Breast Cancer Relapse (CUPCAKE)","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2026-01-05","conditions":"Triple Negative Breast Cancer","enrollment":450},{"nctId":"NCT04251481","phase":"NA","title":"Diffusion MRI for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-10-16","conditions":"Head Cancer Neck","enrollment":16},{"nctId":"NCT06297902","phase":"NA","title":"RAdiotherapy With FDG-PET Guided Dose-PAINTing Compared With Standard Radiotherapy for Primary Head and Neck Cancer-3","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-08-19","conditions":"Head and Neck Cancer, Radiotherapy Side Effect","enrollment":100},{"nctId":"NCT03173924","phase":"PHASE2","title":"18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-06-06","conditions":"Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer","enrollment":96},{"nctId":"NCT03181867","phase":"PHASE2","title":"18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"National Cancer Institute (NCI)","startDate":"2017-08-03","conditions":"Prostate Neoplasms, Prostatic Cancer, Prostate Cancer","enrollment":800},{"nctId":"NCT06199713","phase":"","title":"Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2024-01-30","conditions":"Melanoma, Melanoma Stage III, Melanoma Stage IV","enrollment":24},{"nctId":"NCT07353554","phase":"NA","title":"Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-02-01","conditions":"Multiple Myeloma (MM)","enrollment":30},{"nctId":"NCT07313033","phase":"NA","title":"[68]GA-FAPI-46 PET/CT for the Diagnosis of Metastatic Lesions in Patients With Lobular Breast Cancer (ICL).","status":"NOT_YET_RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2026-03-30","conditions":"Lobular Carcinoma, Breast Cancer","enrollment":45},{"nctId":"NCT07097363","phase":"PHASE2","title":"Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-12-07","conditions":"B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":18},{"nctId":"NCT04333537","phase":"PHASE2, PHASE3","title":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2020-09-23","conditions":"Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma","enrollment":686}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Fludeoxyglucose F 18 (FDG)","genericName":"Fludeoxyglucose F 18 (FDG)","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fludeoxyglucose F-18 is a glucose analog labeled with fluorine-18 that accumulates in tissues with high metabolic activity, enabling detection via positron emission tomography (PET) imaging. Used for Detection and staging of cancer (lung, breast, colorectal, lymphoma, melanoma), Evaluation of dementia and neurodegenerative disorders, Assessment of myocardial viability in cardiac disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}